aetherAI vs GRAIL

Galleri is a multi-cancer blood test that GRAIL's CLIA laboratory runs, and galleri.com states that FDA has not cleared or approved it. GRAIL submitted its PMA in full on January 29, 2026. An FDA advisory panel on September 23, 2026 voted 7 yes, 2 no and 1 abstention that benefits outweigh risks, with effectiveness at 6 yes and 4 no. The randomized NHS-Galleri trial missed its primary endpoint, as a 2026 Diagnosis article and BMJ coverage report. A physician adding a screen for adults 50 and older to guideline screening is the person Galleri serves.

These are different purchases. A clinician orders Galleri, while a pathology department deploys viewer software like aetherSlide. Chang Gung Memorial Hospital, National Taiwan University Hospital and Taipei Veterans General Hospital appear as customers on aetherAI's own About page, a vendor claim.